Atea Pharmaceuticals Announced That The Company's Phase 2 Study Of The Regimen Of Bemnifosbuvir, A Nucleotide Analog Polymerase Inhibitor, And Ruzasvir, An Ns5a Inhibitor, For Treatment Of Hepatitis C Virus Met Its Primary Endpoints Of Safety And...

atea pharmaceuticals宣佈公司的雷替韋託韋與魯扎斯韋聯合用藥治療丙型肝炎病毒的2期研究達到了安全性和主要終點的目標...

Benzinga · 2024/12/04 20:02

Atea Pharmaceuticals Announced That The Company's Phase 2 Study Of The Regimen Of Bemnifosbuvir, A Nucleotide Analog Polymerase Inhibitor, And Ruzasvir, An Ns5a Inhibitor, For Treatment Of Hepatitis C Virus Met Its Primary Endpoints Of Safety And Sustained Virologic Response At 12 Weeks Post-treatment

Atea Pharmaceuticals宣佈公司的Bemnifosbuvir和Ruzasvir聯合方案，即一種核苷類聚合酶抑制劑和一種Ns5a抑制劑，用於治療丙型肝炎病毒的2期研究已在治療後12周達到了安全性和持續病毒學應答的主要終點。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。